Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of WP1122 in Healthy Volunteers
NCT05195723Phase 1Completed
- Sponsor
- Moleculin Biotech, Inc.
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WP-1122 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moleculin Biotech, Inc. Primary endpoints: Safety in Single Ascending Dose (SAD) at 5 weeks and Safety in Multiple Ascending Dose (MAD) at 10 weeks. Started May 2022; status: completed.
02
Drugs
WP-1122
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05195723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195723.